If there is one industry that has grown at a rapid rate and also garnered the attention of investors in a big way due to the possibility of immense growth then it is artificial intelligence. Artificial intelligence is useful for a wide range of industries and leads to much more precise product design in most cases.
One of the niche applications of artificial intelligence is in the field of drug design for the massive pharmaceutical and biotech industries. A company that decided to move in that direction is ImmunoPrecise Antibodies Ltd (NASDAQ IPA). The work is actually been accomplished by BioStrand, which is a subsidiary unit of ImmunoPrecise Antibodies.
BioStrand came up with its own artificial intelligence platform named LENS and back in December last year the company made a significant new announcement on that front. The company announced at the time that it had successfully indexed and encoded as many as 20 million unique biological structures onto LENS.
The big news, in this case, was not about the accomplishment but the actual power of LENS as an artificial intelligence platform. As it happens, the platform is already garnering the attention of many people in the industry due to the sort of scope it offers in drug designing.
The presence of LENS, made it possible for ImmunoPrecise Antibodies to accomplish a quick analysis of antibodies through the use of a computer. However, perhaps the most important thing to keep in mind is that the presence of the LENS platform would allow ImmunoPrecise Antibodies to create therapeutics entirely through the use of a computer.